Commit Biologics Appoints Thomas L. F. Montgomery Andresen, Ph.D., As CEO As Company Prepares To Enter Clinical Development Following €21.5M Seed Backing From Novo Holdings

Commit Biologics, a biotechnology company developing therapies that activate the complement system, announced that Thomas L. F. Montgomery Andresen, Ph.D., has been appointed as Chief Executive Officer. The company, which has raised €21.5 million in seed funding from Novo Holdings, Bioqube Ventures, and Korys, is bringing Dr. Andresen on board at an important stage as it prepares to move into clinical development. He will officially assume the role on March 16, 2026.

Dr. Andresen is a well-known biotech entrepreneur with more than two decades of experience building companies that sit at the intersection of advanced bioengineering and therapeutic innovation. Throughout his career, he has consistently transformed early scientific discoveries into commercially viable technologies, and he has been central in securing substantial institutional support for multiple biotechnology ventures across Europe and the United States.

Anker Lundemose, Chairman of the Board at Commit Biologics, said that Dr. Andresen’s background makes him a strong fit for the company’s next phase. He noted that his history of scientific leadership, paired with his experience as a founder of several biotech companies, will help guide Commit as it works to bring forward new immunotherapies built around complement activation.

In his first comments as incoming CEO, Dr. Andresen shared his enthusiasm for the mission ahead. He explained that Commit is taking a unique approach by leveraging the complement system—an area of the immune system with powerful natural functions that has not yet been fully explored in modern immunotherapy. He highlighted the major advances in immunotherapy over the past two decades, such as checkpoint inhibitors, CAR-T therapies, and T-cell engagers, and expressed his belief that complement-powered immune engagers represent the next breakthrough. He added that the company’s preclinical results have been exceptionally strong, and the non-human primate data in particular makes him confident that similar results will be seen in upcoming clinical trials.

Dr. Andresen also acknowledged the contributions of Chief Scientific Officer Mikkel Wandahl Pedersen, who has served as Interim CEO, thanking him for leading the company through a productive period and helping establish a strong scientific foundation. He expressed his eagerness to work closely with the team to advance therapies that could significantly improve patient outcomes.

Commit Biologics is currently progressing a pipeline built on its Bispecific Complement Engager (BiCE™) technology platform. In November 2025, the company reported positive proof-of-concept data from a non-human primate study. The results showed rapid, deep, and long-lasting depletion of targeted B-cells without causing systemic cytokine release. This provided important validation that the BiCE™ platform can deliver both strong efficacy and a favorable safety profile.

The company expects to name its first two clinical development candidates in 2026. These candidates will target key unmet needs in autoimmune disease and oncology and will form the first wave of a broader pipeline aimed at patient groups where complement activation may offer a meaningful therapeutic advantage. This includes individuals with impaired T-cell function and diseases where existing treatment options remain limited.

Before joining Commit Biologics, Dr. Andresen co-founded several biotech ventures, including Torque Therapeutics, backed by Flagship Pioneering, which was later acquired by Repertoire Immune Medicines. Most recently, he served as founding CEO of T-Cypher Bio, an immunotherapy company based in Oxford and supported by investors such as LifeArc, Oxford Science Enterprises, and Medicxi. He also previously served as founding director of DTU Health Tech at the Technical University of Denmark (DTU). Over the course of his scientific career, he has authored more than 220 research papers and is an inventor on over 50 patent families covering various therapeutic areas.